TY - JOUR T1 - Mobility trends provide a leading indicator of changes in SARS-CoV-2 transmission JF - medRxiv DO - 10.1101/2020.05.07.20094441 SP - 2020.05.07.20094441 AU - Andrew C. Miller AU - Nicholas J. Foti AU - Joseph A. Lewnard AU - Nicholas P. Jewell AU - Carlos Guestrin AU - Emily B. Fox Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/11/2020.05.07.20094441.abstract N2 - Determining the impact of non-pharmaceutical interventions on transmission of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is paramount for the design and deployment of effective public health policies. Incorporating Apple Maps mobility data into an epidemiological model of daily deaths and hospitalizations allowed us to estimate an explicit relationship between human mobility and transmission in the United States. We find that reduced mobility explains a large decrease in the effective reproductive number (RE) attained by April 1st and further identify state-to-state variation in the inferred transmission-mobility relationship. These findings indicate that simply relaxing stay-at-home orders can rapidly lead to outbreaks exceeding the scale of transmission that has occurred to date. Our findings provide quantitative guidance on the impact policies must achieve against transmission to safely relax social distancing measures.Competing Interest StatementJAL and NPJ have received honoraria from Kaiser Permanente unrelated to the current submission. JAL has received research grants and honoraria from Pfizer, research grants and honoraria from Merck, Sharp & Dohme, and honoraria from SutroVax unrelated to the current submission.Funding StatementJAL was supported by a grant from the University of California, Berkeley Population Center.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in the manuscript will be publicly available. Code to reproduce the results will be released on Github.https://www.nytimes.com/article/coronavirus-county-data-us.htmlhttps://covidtracking.comhttps://www.apple.com/covid19/mobility ER -